Abstract Narcolepsy type 1 (NT1) is a chronic sleep disorder resulting from the loss of a
small population of hypothalamic neurons that produce wake-promoting hypocretin (HCRT; …

Objective To define the clinical characteristics, management, and outcome of neurologic
immune-related adverse events (n-irAEs) of immune checkpoint inhibitors (ICIs). Methods …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Objective The contemporary diagnosis of paraneoplastic neurologic syndromes (PNSs)
requires an increasing understanding of their clinical, immunologic, and oncologic …

Background and Objectives To report the clinical, biological, and imaging features and
clinical course of a French cohort of patients with glial fibrillary acidic protein (GFAP) …

Expanding use of immune‐checkpoint inhibitors (ICIs) underscores the importance of
accurate diagnosis and timely management of neurological immune‐related adverse events …

Many tumour antigens that do not arise from cancer cell-specific mutations are targets of
humoral and cellular immunity despite their expression on non-malignant cells. Thus, in …

Background The epidemiology of paraneoplastic neurological syndromes (PNS) remains to
be defined. We present here the first population-based incidence study and report the …

Objective To determine the observed and expected incidence rates of paraneoplastic
neurologic syndromes (PNSs) and autoimmune encephalitides (AEs) diagnosed in France …

Introduction: Immune checkpoint inhibitors (ICI) are associated with a wide spectrum of
neurologic immune-related adverse events (irAEs) including meningo-encephalitis …